elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35957448-50A2FD81-5D05-475B-B0BA-4DCEA945B948
Q35957448-50A2FD81-5D05-475B-B0BA-4DCEA945B948
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35957448-50A2FD81-5D05-475B-B0BA-4DCEA945B948
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
P2860
Q35957448-50A2FD81-5D05-475B-B0BA-4DCEA945B948
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35957448-50A2FD81-5D05-475B-B0BA-4DCEA945B948
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b0e71b82182a70a3b3760f02d29444189b1ac905
P2860
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.